ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASSEMBLY BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.16+0.07 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $380.09M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.29 (−31.54%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ASSEMBLY BIOSCIENCES, INC. grew revenue 125.1% to $74.85M over the twelve months to Jun 30, 2026. Free cash flow was -$38.57M.
Revenue
$74.85M
+125.1% vs. a year earlier
Operating income
-$8.80M
TTM Q2 2026
Free cash flow
-$38.57M
TTM Q2 2026
EPS, diluted
-$0.55
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $380.09M
- P/E ratio
- –
- Price to sales
- 5.08
- Price to book
- 1.24
- Dividend yield
- –
- Free cash flow yield
- -10.15%
Fundamentals
- Revenue
- $74.85M
- Net income
- -$42.00K
- EPS, diluted
- -$0.55
- Free cash flow
- -$38.57M
- Book value per share
- $16.21
- Diluted shares
- 19M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$74.85M+125.1% YoY
Operating income
-$8.80M
Net income
-$42.00K
EPS, diluted
–
Free cash flow
-$38.57M
Reported periodTrailing twelve months